Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2026-06-01 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物关于2022年限制性股票激励计划首次授予部分第三个归属期及预留授予部分（第二批）第二个归属期归属结果暨股票上市公告
Share Issue/Capital Change Classification · 97% confidence The document is a Shanghai Stock Exchange announcement detailing the vesting and listing of restricted shares under a 2022 equity incentive plan, including share quantities, listing dates, capital increase, and share registration proofs. It is not a full financial report or earnings release but an announcement of a capital change (new share issuance under an incentive scheme). This fits the definition of Share Issue/Capital Change (Code: SHA).
2026-06-01 Chinese
益方生物第二届董事会2026年第六次会议决议公告
Regulatory Filings Classification · 84% confidence The document is a public announcement of the board of directors’ meeting resolutions (the second board’s sixth meeting), detailing the agenda, voting results, and proposed authorizations (e.g., approval of a restricted stock incentive plan) that will later be submitted to the shareholders. It does not contain financial statements, earnings data, management changes, nor is it a shareholder vote result at a general meeting. It is a regulatory announcement of internal corporate governance proceedings rather than a formal annual or interim report. Therefore, it best fits the “Regulatory Filings” category (RNS).
2026-05-28 Chinese
益方生物2026年限制性股票激励计划激励对象名单
Share Issue/Capital Change Classification · 85% confidence The document is an announcement of the allocation list for a 2026 restricted stock incentive plan, listing the grantees and amounts. This constitutes an issuance of new shares under an equity incentive plan, i.e., a capital change. It is not a full report, nor an earnings release, nor a management discussion. It matches the Share Issue/Capital Change category (SHA).
2026-05-28 Chinese
益方生物薪酬与考核委员会关于公司2026年限制性股票激励计划（草案）的核查意见
Remuneration Information Classification · 82% confidence The document is an opinion by the Board’s Remuneration and Assessment Committee on the company’s 2026 restricted stock incentive plan (draft). It outlines legal compliance, eligibility, plan structure and governance aspects of the share‐based compensation scheme. This is not an AGM presentation, earnings release, regulatory announcement of report publication, or share issuance notice. It is specifically addressing the company’s remuneration/incentive plan for directors and key employees, matching the Remuneration Information category (DEF 14A).
2026-05-28 Chinese
益方生物2026年限制性股票激励计划实施考核管理办法
Governance Information Classification · 90% confidence The document is a detailed internal policy (‘实施考核管理办法’) outlining governance procedures, performance assessment criteria, roles of board committees and departments in administering the company’s 2026 restricted stock incentive plan. It establishes internal rules and governance practices rather than announcing financial results, dividends, or external regulatory filings. This best fits the Governance Information category.
2026-05-28 Chinese
君合律师事务所上海分所关于益方生物科技（上海）股份有限公司2026年限制性股票激励计划（草案）的法律意见书
Regulatory Filings Classification · 85% confidence The document is a formal legal opinion (“法律意见书”) prepared by an external law firm regarding the company’s proposed 2026 restricted stock incentive plan. It is neither a financial report (10-K, IR, ER), nor a proxy document, nor a management announcement of board changes. It is not reporting on litigation or regulatory enforcement actions, so it does not qualify as a Legal Proceedings Report. Instead, it is a compliance/legal disclosure document to be filed with the exchange, fitting the generic “Regulatory Filings” category (RNS).
2026-05-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.